HLS Therapeutics Inc. (TSE:HLS - Get Free Report) hit a new 52-week high during mid-day trading on Monday . The company traded as high as C$5.10 and last traded at C$5.07, with a volume of 1500 shares. The stock had previously closed at C$4.68.
Analyst Upgrades and Downgrades
Separately, Stifel Nicolaus lifted their target price on shares of HLS Therapeutics from C$3.50 to C$4.00 and gave the company a "hold" rating in a report on Wednesday, March 26th.
View Our Latest Stock Report on HLS
HLS Therapeutics Trading Down 3.0%
The firm has a market capitalization of C$109.01 million, a PE ratio of -4.91 and a beta of 1.07. The company's 50-day moving average price is C$4.44 and its 200-day moving average price is C$4.08. The company has a debt-to-equity ratio of 86.50, a quick ratio of 1.01 and a current ratio of 1.56.
HLS Therapeutics Company Profile
(
Get Free Report)
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.
See Also
Before you consider HLS Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HLS Therapeutics wasn't on the list.
While HLS Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
